Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

The invention discloses the medicinal use of kaurene compound in the prevention and treatment of sepsis, systemic inflammatory response syndrome (SIRS) and multiple organ failure caused by sepsis, including acute pulmonary failure, acute heart failure and renal failure.

The present disclosure relates to compounds that are capable of modulating calcium ion homeostasis and treating disorders related thereto. The disclosure further relates to methods of making the aforementioned compounds.

The present disclosure relates to compounds that are capable of modulating calcium ion homeostasis and treating disorders related thereto. The disclosure further relates to methods of making the aforementioned compounds.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-488 inhibitor in an amount effective to decrease miR-488 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-488 inhibitor in an amount effective to decrease miR-488 suppression of SCN5A mRNA transcription. A method of decreasing arrhythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-488 inhibitor in an amount effective to decrease miR-488 suppression of SCN5A mRNA transcription. A method of treating arrhythmia in a patient having, or at risk of having, arrhythmia generally includes administering to the patient an miR-488 inhibitor in an amount effective to decrease the likelihood or extent of arrhythmia in the patient. In some embodiments of all methods, the miR-488 inhibitor can be an miR-488 antagomir or an miR-488 sponge.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-488 inhibitor in an amount effective to decrease miR-488 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-488 inhibitor in an amount effective to decrease miR-488 suppression of SCN5A mRNA transcription. A method of decreasing arrhythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-488 inhibitor in an amount effective to decrease miR-488 suppression of SCN5A mRNA transcription. A method of treating arrhythmia in a patient having, or at risk of having, arrhythmia generally includes administering to the patient an miR-488 inhibitor in an amount effective to decrease the likelihood or extent of arrhythmia in the patient. In some embodiments of all methods, the miR-488 inhibitor can be an miR-488 antagomir or an miR-488 sponge.

Disclosed herein are compositions and methods for use in treating cardiovascular disorders.

Disclosed herein are compositions and methods for use in treating cardiovascular disorders.